Update of enterovirus 71 infection: Epidemiology, pathogenesis and vaccine

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 4, 2014, Pages 447-456

  Wang, Shih Min ^a,b   Liu, Ching Chuan ^b,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

brain stem encephalitis; enterovirus 71; hand foot and mouth disease; receptor; vaccine

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; P SELECTIN GLYCOPROTEIN LIGAND 1; SCAVENGER RECEPTOR B; SCAVENGER RECEPTOR B2; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; VIRUS RECEPTOR; VIRUS VACCINE;

ANTIBODY RESPONSE; CROSS REACTION; DISEASE MODEL; DISEASE SEVERITY; ENTEROVIRUS 17 INFECTION; ENTEROVIRUS 71 INFECTION; ENTEROVIRUS INFECTION; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; NONHUMAN; PATHOGENESIS; REVIEW; VIRUS ATTACHMENT; VIRUS ENTRY; ANIMAL; ENTEROVIRUS; HAND, FOOT AND MOUTH DISEASE; IMMUNOLOGY; PATHOGENICITY; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; ENTEROVIRUS A, HUMAN; HAND, FOOT AND MOUTH DISEASE; HUMANS; RECEPTORS, VIRUS; VIRAL VACCINES;

EID: 84896348198     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.895666     Document Type: Review

References (91)

1. Schmidt NJ, Lennett EH, Ho HH. An apparently new enterovirus isolated from patients with disease of central nervous system. J Infect Dis 1974;129:304-9
2. McMinn PC. The emergence of enterovirus 71 as a major cause of acute neurological disease in young children of the Asia-Pacific region. J Pediatr Infect Dis 2006;1:17-23
3. Wang SM, Liu CC. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther 2009;7:735-42
4. Wang SM, Ho TS, Lin HC, et al. Reemerging of enterovirus 71 in Taiwan: the age impact on disease severity. Eur J Clin Microbiol Infect Dis 2012;31: 1219-24
5. Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010;10:778-90
6. Christian KA, Ijaz K, Dowell SF, et al. What we are watching five top global infectious disease threats, 2012: a perspective from CDC's Global Disease Detection Operations Center. Emerg Health Threats J 2013;6:20632
7. WHO. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). WHO; Geneva, Switzerland: 2011
8. Wang SM, Liu CC, Tseng HW, et al. Clinical spectrum of enterovirus 71 infection of children in southern Taiwan, with an emphasis on the neurological complications. Clin Infect Dis 1999;29:184-90
9. Wang SM, Lei HY, Huang MC, et al. Therapeutic efficacy of milrinone in the management of enterovirus 71-induced pulmonary edema. Pediatr Pulmonol 2005;39:219-23
10. Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010;9:1097-105
11. Huang MC, Wang SM, Hsu YW, et al. Long-term cognitive and motor deficits following enterovirus 71 brainstem encephalitis in children. Pediatrics 2006;118:e1785-8
12. Brown BA, Oberste MS, Alexander JP Jr, et al. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 1999;73:9969-75
13. Deshpande JM, Nadkarni SS, Francis PP. Enterovirus 71 isolated from a case of acute flaccid paralysis in India represents a new genotype. Curr Sci 2003;84:1350-3
14. Huang YP, Lin TL, Lin TH, Wu HS. Antigenic and genetic diversity of human enterovirus 71 from 2009 to 2012, Taiwan. PLoS One 2013;8:e80942
15. Wu WH, Kuo TC, Lin YT, et al. Molecular epidemiology of enterovirus 71 infection in the central region of Taiwan from 2002 to 2012. PLoS One 2013;8: e83711
16. Lee MS, Lin ZY, Chiang PS, et al. An investigation of epidemic enterovirus 71 infection in Taiwan, 2008: clinical, virologic, and serologic features. Pediatr Infect Dis J 2010;29:1030-4
17. AbuBakar S, Sam IC, Yusof J, et al. Enterovirus 71 outbreak, Brunei. Emerg Infect Dis 2009;15:79-82
18. Wu Y, Yeo A, Phoon MC, et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: The role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010;14:e1076-81
19. Badran SA, Midgley S, Andersen P, Bo?ttiger B. Clinical and virological features of enterovirus 71 infections in Denmark, 2005 to 2008. Scand J Infect Dis 2011;43: 642-8
20. Huang SW, Hsu YW, Smith DJ, et al. Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol 2009;47:3653-62
21. He SJ, Han JF, Ding XX, et al. Characterization of enterovirus 71 and coxsackievirus A16 isolated in hand, foot, and mouth disease patients in Guangdong, Int J Infect Dis 2013;17:e1025-30
22. Tan X, Huang X, Zhu S, et al. The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 2011;6:e25662
23. Biswas T. Enterovirus 71 causes hand, foot and mouth disease outbreak in Cambodia. Natl Med J India 2012;25:316
24. Ryu WS, Kang B, Hong J. Enterovirus 71 infection with central nervous system involvement, South Korea. Emerg Infect Dis 2010;16:1764-6
25. Zhang Y, Wang J, Guo W, et al. Emergence and transmission pathways of rapidly evolving evolutionary branch C4a strains of human enterovirus 71 in the central plain of China. PLoS One 2011;6: e27895
26. Thoa LPK, Chiang PS, Khanh TH, et al. Genetic and antigenic characterization of enterovirus 71 in Ho Chi Minh City, Vietnam, 2011. PLoS One 2013;8:e69895
27. Wu JS, Zhao N, Pan H, et al. Patterns of polymorphism and divergence in the VP1 gene of enterovirus 71 circulating in the Asia-Pacific region between 1994 and J Virol Methods 2013;193:713-28
28. Schuffenecker I, Mirand A, Antona D, et al. Epidemiology of human enterovirus 71 infections in France, 2000-2009. J Clin Virol 2011;50:50-6
29. van der Sanden S, Koopmans M, Uslu G, van der Avoort H. Epidemiology of enterovirus 71 in the Netherlands, 1963 to J Clin Microbiol 2009;47:2826-33
30. McWilliam Leitch MC, Cabrerizo M, Cardosa J, et al. The association of recombination events in the founding and emergence of subgenogroup evolutionary lineages of human enterovirus 71. J Virol 2012;86:2676-85
31. Chang HL, Chio CP, Su HJ, et al. The association between enterovirus 71 infections and meteorological parameters in Taiwan. PLoS One 2012;7:e46845
32. Heffernan JM, Smith RJ, Wahl LM. Perspectives on the basic reproductive ratio. J R Soc Interface 2005;2:281-93
33. Ma E, Fung C, Yip SH, et al. Estimation of the basic reproduction number of enterovirus 71 and coxsackievirus A16 in hand, foot, and mouth disease outbreaks. Pediatr Infect Dis J 2011;30:675-9
34. Ruan F, Yang T, Ma H, et al. Risk factors for hand, foot, and mouth disease and herpangina and the preventive effect of hand-washing. Pediatrics 2011;127: e898-904
35. Dimitrov DS. Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2004;2:109-22
36. Nishimura Y, Shimojima M, Tano Y, et al. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 2009;15:794-8
37. Wang SM, Lei HY, Liu CC. Cytokine immunopathogenesis of enterovirus 71 brain stem encephalitis. Clin Develop Immunol 2012;2012:876241
38. Nishimura Y, Wakita T, Shimizu H. Tyrosine sulfation of the amino terminus of PSGL-1 is critical for enterovirus 71 infection. PLoS Pathog 2010;6: e1001174
39. Nishimura Y, Lee H, Hafenstein S, et al. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog 2013;9:e1003511
40. Yamayoshi S, Yamashita Y, Li J, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 2009;15: 798-801
41. Yamayoshi S, Iizuka S, Yamashita T, et al. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J Virol 2012;86: 5686-96
42. Lin HY, Yang YT, Yu SL, et al. Caveolar endocytosis is required for human PSGL-1-mediated enterovirus 71 infection. J Virol 2013;87:9064-76
43. Yamayoshi S, Ohka S, Fujii K, Koike S. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol 2013;87:3335-47
44. Yang SL, Chou YT, Wu CN, Ho MS. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol 2011;85:11809-20
45. Tan CW, Poh CL, Sam IC, Chan YF. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 2013;87:611-20
46. Su PY, Liu YT, Chang HY, et al. Cell surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and neuroblastoma cells. BMC Microbiol 2012;12:162
47. Chen YC, Yu CK, Wang YF, et al. A murine oral enterovirus 71 infection model with central nervous system involvement. J Gen Virol 2004;85:69-77
48. Ohka S, Sakai M, Bohnert S, et al. Receptor-dependent and -independent axonal retrograde transport of poliovirus in motor neurons. J Virol 2009;83: 4995-5004
49. Griffiths MJ, Ooi MH, Wong SC, et al. In enterovirus 71 encephalitis with cardiorespiratory compromise, elevated interleukin 1, interleukin 1 receptor antagonist, and granulocyte colony-stimulating factor levels are markers of poor prognosis. J Infect Dis 2012;206:881-92
50. Lin TY, Hsia SH, Huang YC, et al. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis 2003;36: 269-74
51. Khong WX, Foo DGW, Trasti SL, et al. Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J Virol 2011;85:3067-76
52. Wang SM, Lei HY, Huang MC, et al. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol 2006;37:47-52
53. Wang SM, Lei HY, Yu CK, et al. Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. J Infect Dis 2008;198: 1002-6
54. Shen FH, Tsai CC, Wang LC, et al. Enterovirus 71 infection increases expression of interferon-gamma-inducible protein 10 which protects mice by reducing viral burden in multiple tissues. J Gen Virol 2013;94:1019-27
55. Chen J, Tong J, Liu H, et al. Increased frequency of Th17 cells in the peripheral blood of children infected with enterovirus J Med Virol 2012;84:763-7
56. Yang J, Zhao N, Su NL, et al. Association of interleukin 10 and interferon gamma gene polymorphisms with enterovirus 71 encephalitis in patients with hand, foot and mouth disease. Scand J Infect Dis 2012;44:465-9
57. Gong X, Zhou J, Zhu W, et al. Excessive proinflammatory cytokine and chemokine responses of human monocyte-derived macrophages to enterovirus 71 infection. BMC Infect Dis 2012;12:224
58. Deng L, Jia HL, Liu CW, et al. Proteomic analysis of extremely severe hand, foot and mouth disease infected by enterovirus 71. BMC Infect Dis 2013;13:383
59. Wang SM, Lei HY, Huang KJ, et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: the roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis 2003;188:564-70
60. Lin YW, Chang KC, Kao CM, et al. Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. J Virol 2009;83:6477-83
61. Xie J, Jiao Y, Qiu Z, et al. Significant elevation of B cells at the acute stage in enterovirus 71-infected children with central nervous system involvement. Scand J Infect Dis 2010;42:931-5
62. Lin YW, Wang SW, Tung YY, Chen SH. Enterovirus 71 infection of human dendritic cells. Exp Biol Med 2009;234:1166-73
63. Zhang Y, Cui W, Liu L, et al. Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest 2011;91:1337-50
64. Huang SW, Lee YP, Hung YT, et al. Exogenous interleukin-6, interleukin-13, and interferon -. provoke pulmonary abnormality with mild edema in enterovirus 71-infected mice. Respir Res 2011;12:147
65. Fujii K, Nagata N, Sato Y, et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci USA 2013;110:14753-8
66. Lin YW, Yu SL, Shao HY, et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One 2013;8:e57591
67. Chang HW, LinYW, Ho HM, et al. Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice. PLoS One 2013;8:e69858
68. Khong WX, Yan B, Yeo H, et al. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol 2012;86:2121-31
69. Caine EA, Partidos CD, Santangelo JD, Osorio JE. Adaptation of enterovirus 71 to adult interferon deficient mice. PLoS One 2013;8:e59501
70. Luo ST, Chiang PS, Chao AS, et al. Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis 2009;15: 581-4
71. Chen KT, Chang HL, Wang ST, et al. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005. Pediatrics 2007;120:e244-52
72. Gantt S, Yao L, Kollmann TR, et al. Implications of age-dependent immune responses to enterovirus 71 infection for disease pathogenesis and vaccine design. J Pediatr Infect Dis Soc 2013;2:162-70
73. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977;146:201-17
74. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003;13:387-98
75. Wang SM, Chen IC, Su LY, et al. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin Vaccine Immunol 2010;17:1517-23
76. Han JF, Cao RY, Deng YQ, et al. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J 2011;8:106
77. Chen IC, Wang SM, Yu CK, Liu CC. Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice. Med Microbiol Immunol 2013;202:259-65
78. Cao RY, Dong DY, Liu RJ, et al. Human IgG subclasses against enterovirus type 71: neutralization versus antibody dependent enhancement of infection. PLoS One 2013;8:e64024
79. Xu J, Qian Y, Wang S, et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine 2010;28:3516-21
80. Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010;9:149-56
81. Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 2010;84:661-5
82. Bek EJ, Hussain KM, Phuektes P, et al. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 2011;29:4829-38
83. Chou AH, Liu CC, Chang JY, et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One 2013;8:e79783
84. Li YP, Liang ZL, Gao Q, et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 2012;30:3295-303
85. Zhu FC, Wang JZ, Li XL, et al. Reactogenicity and immunogenicity of an enterovirus 71 vaccine in Chinese healthy children and infants. Pediatr Infect Dis J 2012;31:1158-65
86. Zhu FC, Liang ZL, Li XL, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomized, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013;381: 1037-45
87. Li YP, Liang ZL, Xia JL, et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, randomized, double-blind, placebo-controlled trial. J Infect Dis 2014;209:46-55
88. Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2013;381:2024-32
89. Mao Q, Cheng T, Zhu F, et al. The cross-neutralizing activity of enterovirus 71 subgenotype C4 vaccines in healthy Chinese infants and children. PLoS One 2013;8:e79599
90. Hu YM, Wang X, Wang JZ, et al. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol 2013;20: 1805-11
91. Chen CW, Lee YP, Wang YF, Yu CK. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine 2011;29: 2772-6